Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET: Rituximab safety and effectiveness in rheumatoid arthritis after inadequate response to one anti-TNF inhibitor
2006-001682-42Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Primary safety endpoint. Started Jun 2006; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-001682-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001682-42.